Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 54.02 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Crinetics Pharmaceuticals Inc < Previous 1 2 3 4 5 6 Next > 9 Analysts Have This to Say About Crinetics Pharmaceuticals August 31, 2023 Via Benzinga Analyst Expectations for Crinetics Pharmaceuticals's Future August 09, 2023 Via Benzinga Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023 June 21, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics to Highlight Broad Pipeline at ENDO 2023 June 09, 2023 Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Where Crinetics Pharmaceuticals Stands With Analysts June 08, 2023 Via Benzinga The Latest Analyst Ratings for Crinetics Pharmaceuticals April 24, 2023 Via Benzinga Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update May 04, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 April 24, 2023 Via Benzinga Crinetics Pharmaceuticals's Return On Capital Employed Overview December 26, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 March 30, 2023 Via Benzinga Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update February 28, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference February 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference January 09, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 12, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Provides Update on CRN04777 Program November 28, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference November 22, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly October 13, 2022 Topline results for PATHFNDR-1 study expected in Q3 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism October 06, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer October 03, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals's Return On Capital Employed Overview September 09, 2022 Benzinga Pro data, Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 sales of $439 thousand. Earnings fell to a loss of $42.38 million, resulting in a 22.38% decrease from last quarter. Via Benzinga Crinetics Pharmaceuticals: Q2 Earnings Insights August 12, 2022 Crinetics Pharmaceuticals (NASDAQ:CRNX) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga Crinetics Pharmaceuticals Announces Positive Top-line Results From CRN04894 Early-Stage Trial May 25, 2022 Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) revealed positive topline results from a first-in-human Phase 1 clinical study of CRN04894 for the treatment of patients with Cushing's disease. Via Benzinga The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine May 25, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga 88 Biggest Movers From Yesterday May 26, 2022 Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw... Via Benzinga The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More April 13, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.